Zimmer Biomet stock (US98956P1021): knee and hip specialist in focus after latest quarter

Zimmer Biomet has reported new quarterly figures and updated its outlook, putting the medical technology group and its orthopedic implants back in the spotlight for investors in Europe and the US.

Zimmer Biomet has recently presented new quarterly results and adjusted its outlook for the current financial year, drawing fresh attention to the medical technology group and its orthopedic implant portfolio among investors in Europe and the United States, according to the company’s earnings release published in early May 2026 and coverage by major financial media on the same date.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Zimmer Biomet
• Sector/industry: Medical technology, orthopedic implants
• Headquarters/country: United States
• Core markets: Orthopedic surgery, sports medicine, spine and craniomaxillofacial products
• Key revenue drivers: Knee and hip replacement systems, surgical tools and related technologies
• Home exchange/listing venue: New York Stock Exchange (ticker: ZBH)
• Trading currency: USD

Zimmer Biomet: core business model

Zimmer Biomet develops, manufactures and markets medical devices with a strong focus on musculoskeletal health. The company’s portfolio spans knee and hip replacement systems, extremities implants, trauma products and related surgical instruments that are used by hospitals and clinics worldwide in orthopedic and reconstructive procedures.

The business model centers on close collaboration with surgeons and healthcare providers. Zimmer Biomet invests in product training, clinical support and digital planning tools designed to help specialists plan and execute complex joint replacement procedures, which in turn can deepen customer relationships and support recurring demand for implants and instruments over long product lifecycles.

A significant part of the company’s revenue is generated through elective procedures such as knee and hip replacements. These surgeries depend on hospital capacity, patient willingness to undergo operations and reimbursement frameworks, which can create sensitivity to macroeconomic factors and healthcare policy decisions in core markets like the United States and Europe.

Main revenue and product drivers for Zimmer Biomet

The largest revenue contribution traditionally comes from large joint reconstruction, particularly knee and hip implants. These segments benefit from demographic trends such as aging populations and rising prevalence of degenerative joint diseases, especially in developed markets, where access to advanced orthopedic care is widespread and reimbursement systems are established.

Beyond large joints, Zimmer Biomet is active in extremities, trauma, spine and related biological solutions. These areas include implants for shoulder, elbow and other joints, as well as systems used in fracture fixation and spinal surgery. While smaller in absolute terms than hip and knee, these product lines broaden the portfolio and offer exposure to trauma and sports medicine procedures.

The company also derives revenue from surgical tools, navigation systems and digital platforms that support planning and intraoperative guidance. These technologies can help integrate Zimmer Biomet products into hospital workflows and may encourage standardization around the company’s ecosystem, potentially supporting long-term equipment and consumables sales.

Why Zimmer Biomet matters for US investors

Zimmer Biomet is one of the larger pure-play orthopedic device manufacturers listed on the New York Stock Exchange, making the stock a way for US investors to gain targeted exposure to musculoskeletal health and joint replacement trends. The company’s results can offer insight into procedure volumes in US hospitals and demand for elective surgeries.

Because a substantial share of revenue is generated in the United States, Zimmer Biomet is sensitive to US healthcare utilization, reimbursement developments and hospital capital spending. Shifts in insurance coverage, policy changes or broader macroeconomic trends that affect patient behavior can influence surgical volumes and, by extension, the company’s sales and margins.

In addition, Zimmer Biomet competes with other global medtech players in the orthopedic segment. For investors focused on the US healthcare sector, the company’s performance relative to peers may serve as one indicator of how competitive dynamics and innovation cycles are unfolding within the broader medical device industry.

Conclusion

Zimmer Biomet remains a globally active medical technology group with a clear focus on orthopedic and musculoskeletal products, from large joint replacements to extremities and trauma solutions. The company’s financial updates and outlook are closely watched because they can shed light on surgical volumes, hospital spending and demographic demand trends.

For investors, the stock combines exposure to aging populations and elective orthopedic procedures with the typical risks of the medtech sector, such as regulatory changes, competition and innovation cycles. How Zimmer Biomet executes on its strategy, manages its product pipeline and responds to healthcare system dynamics will likely remain key factors for the market’s assessment of the shares over the medium term.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.